In a case concerning socket assemblies used in prosthetic hip implants, Howmedica Osteonics Corp. and Stryker Ireland Ltd. (collectively "Stryker") appealed from the District of New Jersey's noninfringement ruling...

The Federal Circuit affirmed the Patent Trial and Appeal Board's ("PTAB") determination that various claims of a patent, directed to LED technology, were unpatentable as obvious.

As set forth in the decision, Mylan's failure to respond to a deficiency letter received from FDA in May 2014 "raise[d] serious questions in the Court's mind as to the viability of Mylan's ANDA product as currently formulated."

Glenmark Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Inc., USA ("Glenmark"), the filers of an Abbreviated New Drug Application ("ANDA") for a topical skin treatment...

In Romag Fasteners, Inc. v. Fossil, Inc., the Federal Circuit decided two issues. First, the Federal Circuit confirmed that laches can be a defense to legal relief in a patent-infringement suit.

The Federal Circuit held that Merck's offer for sale more than one year prior to the patent's filing date was sufficiently definite to constitute an on-sale bar against U.S. Patent No. 6,441,168...

An arbitral tribunal typically possesses broad powers to set the procedures within an arbitration, including the appointment and management of its own expert to assist the tribunal with technical subjects...

The District of New Jersey entered a Final Judgment ending a Hatch-Waxman patent infringement lawsuit and protecting innovator pharmaceutical company Shire's blockbuster drug Vyvanse® (lisdexamfetamine dimesylate).

The PTO initiated a reexamination and deemed the amended and additional claims to be patentable, but not before the Federal Circuit affirmed the district court's judgment of invalidity due to ineligibility under 35 U.S.C. § 101.

On October 16, 2015, FLH represented Shire in a class certification hearing before Magistrate Judge Goodman in the Southern District of Florida.

On September 24, 2015, the U.S. Court of Appeals for the Federal Circuit affirmed summary judgment of non-obviousness of 18 claims from four patents protecting Shire's blockbuster drug Vyvanse...

Shire Pharmaceuticals has just achieved another victory in the enforcement of its Lialda® patent.

Can you patent your blockchain?

The district court rejected GeoTag's assertion that Google's declaratory-judgment claims lacked sufficient detail to warrant the exercise of subject-matter jurisdiction, and granted summary judgment of noninfringement to Google.

The Patent Trials and Appeals Board issued two decisions denying institution of inter partes review for U.S. Patent No. 8,215,865 ("the '865 patent")...

TC Heartland LLC ("Heartland") petitioned for a writ of mandamus to direct the Delaware District Court to dismiss or transfer the patent-infringement suit filed against it by Kraft Foods.

Ready-to-use CARDENE® I.V. Premixed Injection is indicated for the short-term treatment of hypertension and is the only available FDA-approved premixed formulation of nicardipine hydrochloride.

On September 24, 2015, the U.S. Court of Appeals for the Federal Circuit affirmed summary judgment of non-obviousness of 18 claims from four patents protecting Shire's blockbuster drug Vyvanse® (lisdexamfetamine dimesylate).

On February 15, 2020, a rule change went into effect requiring trademark Applicants and Registrants to list a working email address at the USPTO.

FLH is particularly pleased to be able to protect this important Supernus franchise, which was attacked by Actavis only a few months after Oxtellar XR®'s February 2013 launch.